Peripherally acting |Ll-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy

Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting [micro]-opioid receptor antagonists...

Full description

Saved in:
Bibliographic Details
Published in:Patient preference and adherence 2017-01, Vol.11, p.107
Main Authors: Pergolizzi, Joseph V, Raffa, Robert B, Pappagallo, Marco, Fleischer, Charles, Pergolizzi, Joseph, Zampogna, Gianpietro, Duval, Elizabeth, Hishmeh, Janan, LeQuang, Jo Ann, Taylor, Robert
Format: Article
Language:English
Subjects:
Combination drug therapy
Complications and side effects
Constipation
Dosage and administration
Drug therapy
Management
Methods
Opioid receptors
Opioids
Pain management
Patient compliance
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Opioid-induced constipation (OIC), a prevalent and distressing side effect of opioid therapy, does not reliably respond to treatment with conventional laxatives. OIC can be a treatment-limiting adverse event. Recent advances in medications with peripherally acting [micro]-opioid receptor antagonists, such as methylnaltrexone, naloxegol, and alvimopan, hold promise for treating OIC and thus extending the benefits of opioid analgesia to more chronic pain patients. Peripherally acting [micro]-opioid receptor antagonists have been clinically tested to improve bowel symptoms without compromise to pain relief, although there are associated side effects, including abdominal pain. Other treatment options include fixed-dose combination products of oxycodone analgesic together with naloxone. Keywords: opioid-induced constipation, opioid bowel disorder, PAMORA, peripherally acting mu-opioid receptor antagonist, noncancer pain patients, opioid-associated side effects
ISSN:1177-889X
1177-889X
DOI:10.2147/PPA.S780